The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be included. A comparison will be made between the effectiveness of intralesional Triamcinolone (standard first-line treatment) and intralesional Candida albicans antigen, with serial clinical and trichoscopic pictures at follow-up to evaluate the clinical response and associated adverse effects.

Inclusion Criteria:

• Diagnosis of alopecia areata
• SALT score of less than 50% extension
• Has not received any topical or systemic treatment in the last month
• Signed informed consent

Exclusion Criteria:

• Any skin condition on the scalp (infectious, inflammatory or neoplastic) that could modify the clinical of trichoscopic features
• Pregnancy or breast-feeding
• Patients in medications that could cause hair loss as side-effects

The database with the main clinical and trichoscopic results could be shared